remdesivir + NA-831

This is a **combination drug** comprised of **remdesivir** and **NA-831**. Remdesivir is a nucleotide analog antiviral agent, originally developed by Gilead Sciences, that inhibits viral RNA-dependent RNA polymerase and is approved for the treatment of COVID-19. NA-831 is a small molecule neuroprotective agent, under development by Biomed Industries and NeuroActiva, which promotes neurogenesis, neuroprotection, and potentially improves cognitive function. NA-831 acts by stimulating synaptic AMPA receptors and increasing the expression of BDNF (brain-derived neurotrophic factor), with the overall aim to restore hippocampal neurogenesis and prevent or slow cognitive decline, especially in Alzheimer’s disease. Clinical trials are being conducted for the combination, particularly testing an **inhaled nanoparticle formulation** for remdesivir with NA-831, targeting both antiviral activity and neuroprotection, especially in the context of COVID-19 and associated neurological complications. Preclinical and early clinical studies suggest this combination may offer enhanced efficacy for reducing neurological sequelae in patients with viral infections, particularly SARS-CoV-2[1][3][7][9].

Brand names

Veklury

Other names

remdesivir + NA-831